New details on Johnson & Johnson’s (NYSE:JNJ) marketing of its controversial transvaginal mesh implants are again in the spotlight as unsealed documents suggest that the healthcare giant sold the devices for an additional 9 months after the FDA deemed the products adulterated and asked J&J to pull them off the shelves.
Women's Health
Women’s health company Viveve names Patricia Scheller CEO | Personnel Moves
Women’s health devices maker Viveve appoints Patricia Scheller CEO
Privately held Viveve today named Patricia Scheller CEO, also adding her to the company’s board of directors.
Scheller has spent more than 25 years in the health care industry, including as CEO of Prescient Medical and SomaLogic.
MassDevice.com +3 | The top 3 med-tech stories for June 5, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
J&J’s decision to pull women’s mesh is not a recall
Johnson & Johnson (NYSE:JNJ) isn’t recalling its controversial transvaginal mesh products, but is pulling them off the shelves in response to the more than 600 women who have filed lawsuits claiming personal injury as a result of having receiving the implants.
Breast implants: More women affected by PIP scandal
New reports from the U.K.’s Medicines & Healthcare Products Regulatory Agency warn that even more women may have received breast implants with substandard silicone that’s prone to rupture.
The agency advised health care providers to begin assessing patients who received breast implants made by Poly Implant Prosthèse, expanding the warning which originally applied only to implants distributed after January 2001.
FDA’s role in promoting women’s health
By: Marsha Henderson, M.C.R.P.
For one week in May, the nation celebrates women’s health. I often find at these celebrations that no one mentions FDA. This is unfortunate, because throughout its100-year history FDA has played a leading role in advancing women’s health.
Bard transvaginal mesh lawsuits begin in February | Legal News
Sitting pretty: Even in recession-ravaged countries in Southern Europe, beauty sells | Earnings Roundup
Despite a crippling recession which puts it in the epicenter of the European debt crisis, it still seems Southern Europe puts a premium on not just the beauty of its land, but those of its people as well.
On Wednesday Allergan (NYSE:AGN) reported stronger than expected sales of its breast implants, Botox and other aesthetic devices in places like Spain, where the unemployment rate tips 24% – more than 3 times that of the U.S.
MassDevice.com +3 | The top 3 med-tech stories for May 3, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
An upside to the European PIP breast implant scandal?
Far from chilling the breast aesthetics market, the widespread breast implant recall in Europe may have an upside for device makers as patients opt to replace their potentially rupture-prone implants.
When French breast modification company Poly Implant Prosthèse was caught filling its breast implants with substandard silicone, rival implant makers took pains to distance themselves from the scandal for fear of being tangled in a PR nightmare.